Biotech Values

[stuck_holder]

If Provenge is as promising as some people think, surely there are ample sources of capital to complete the clinical program.

if Provenge is safe (and the AC experts unanimously & emphatically said it was via their 17-0 vote, even with knowledge of the CVA side effects in a small number of patients) and that 9901/9902A Provenge trials have demonstrated substantial evidence of efficacy, why should its approval and public availability be delayed? just because some anal retentive and/or conflicted hypocritic doctor wants to protect the turf they feel is being threatened?

as far as ample sources of capital, it appears that there is an equal if not greater source of counterfeit DNDN shares thanks to a corrupted marketplace and regulatory environment to suppress the price/value of the stock. are you now trying to suggest the market is being efficient regarding the valuation of DNDN???

a rather curious commentary i must say.